No Data
No Data
Shanghai Shenqi Pharmaceutical Investment Management (stock code: 600613.SH) 2023 equity distribution: 0.1 yuan per share.
Shanghai Shenqi Pharmaceutical Investment Management (stock code 600613.SH) has announced the equity distribution plan for the fiscal year 2023: based on the total share capital before the implementation of the plan, a cash dividend of 0.10 yuan (including tax) per share will be distributed, with the ex-dividend date on June 18, 2024 and the record date on June 17, 2024.
We Like The Quality Of Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Earnings
Magic Pharmaceutical (600613.SH) announced first-quarter results, net profit of 239.447 million yuan, an increase of 0.65%
According to Zhitong Finance App News, Magic Pharmaceutical (600613.SH) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 575 million yuan, a year-on-year decrease of 1.42%. Net profit attributable to shareholders of listed companies was 239.447 million yuan, an increase of 0.65% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 237.719 million yuan, an increase of 1.11% over the previous year.
Magic Pharmaceutical (600613.SH) announced its 2023 annual results, with net profit of 57.007 million yuan, an increase of 17.41% year-on-year
Magic Pharmaceutical (600613.SH) released its 2023 annual performance report. The company achieved operating income of 2 during the reporting period...
The controlling shareholder of Magic Pharmaceutical (600613.SH) plans to transfer 5.62% of its shares to Zhiji 2 at a price of 192 million yuan
Magic Pharmaceutical (600613.SH) announced that the controlling shareholder of the company, Guizhou Magic Holdings (Group) Co., Ltd. (abbreviation...
Magic Pharmaceutical (600613.SH): Subsidiary company obtained high-tech enterprise certificate
Gelonghui, Feb. 22 | Magic Pharmaceutical (600613.SH) announced that its holding subsidiaries, Guizhou Magic Pharmaceutical Co., Ltd., Guizhou Bai Compulsory Pharmaceutical Co., Ltd., and its subsidiary company Guizhou Junzhitang Pharmaceutical Co., Ltd. recently received the “High-tech Enterprise Certificate” jointly issued by the Guizhou Provincial Department of Science and Technology, the Guizhou Provincial Department of Finance, and the Guizhou Provincial Taxation Bureau of the State Administration of Taxation.
No Data